Tedizolid phosphate (Sivextro): A Second-Generation Oxazolidinone to Treat Acute Bacterial Skin and Skin Structure Infections

P and T

Volumn 39, Issue 8, 2014, Pages

  Wong, Elaine ^a   Rab, Saba ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84905716041     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (22)

1. McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureusassociated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006;12(11):1715-1723.
2. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. Available at: http://www. fda.gov/downloads/Drugs/./Guidances/ ucm071185.pdf. Accessed February 4, 2014.
3. Itani KM, Shorr AF. FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials. Clin Infect Dis2014;58(S1):S4-9.
4. Corey GR, Stryjewski ME. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. Clin Infect Dis2011;52(S7):S469-S476.
5. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis2005;41:1373-1406.
6. Zyvox (linezolid) prescribing information. New York, New York; Pharmacia & Upjohn Co.; 2013. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=649. Accessed February 4, 2014.
7. Toh S-M, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureusresistant to the synthetic antibiotic linezolid. Mol Microbiol 2007;64(6):1506-1514.
8. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfrgene in the first report of an outbreak of linezolidresistant Staphylococcus aureus. Clin Infect Dis2010;50(6):821-825.
9. Kanafani Z, Corey GR. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs2012;21(4):515-522.
10. Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011;55(2):583-592.
11. Sivextro (tedizolid phosphate) prescribing information. Lexington, Massachusetts; Cubist Pharmaceuticals U.S.; 2014. Available at: http://sivextro.com/pdf/PrescribingInformation.pdf. Accessed July 9, 2014.
12. Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs. linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA.2013;306(6)559-569.
13. Rodriguez-Avial I, Culebras E, Betriu C, et al. In vitroactivity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother2012;67(1):167-169.
14. Choi S, Im W, Bartizal K. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. Antimicrob Agents Chemother 2012;56(9):4713-4717.
15. Lepak AJ, Marchillo K, Pichereau S, et al. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureuspneumonia model. Antimicrob Agents Chemother2012;56(11):5916-5922.
16. Keel RA, Tessier PR, Crandon JL, Nicolau DP. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureusin the murine thigh infection model. Antimicrob Agents Chemother2012;56(8):4403-4407.
17. Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother 2012;56(5):2627-2634.
18. Sahre M, Sabarinath S, Grant M, et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents. 2012;40(1):51-54.
19. Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomized, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis2014. doi: 10.1016/S1473-3099(14)70737-6. [Epub ahead of print].
20. Flanagan S, Bartizal K, Minassian SL, et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother 2013;57(7):3060-3066.
21. Red book Online. Ann Arbor, Michigan: Truven Health Analytics. Accessed July 14, 2014.
22. ClinicalTrials. gov. TR-701 FA vs linezolid for the treatment of nosocomial pneumonia [July 13, 2014]. Available at: http://clinicaltrials.gov/ct2/show/ NCT02019420?term=tr-701&rank=7. Accessed July 14, 2014.